JPRN-jRCT2080224946已完成3 期
A Phase III, double blind, randomized study of Bevacizumab in combination with Carboplatin or Cisplatin + Etoposide + Atezolizumab compared with Carboplatin or Cisplatin + Etoposide + Atezolizumab in patients with untreated ES-SCLC
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 330
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Histologically or cytologically confirmed ES-SCLC
- •- No prior treatment for ES-SCLC
- •- ECOG performance status of 0 or 1
- •- Measurable disease, as defined by RECIST v1.1
- •- Adequate hematologic and end organ function
排除标准
- •- Malignancies other than SCLC within the last 5 years
- •- Pregnant or lactating women
- •- History of autoimmune disease
- •- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.
- •- Positive test for Human Immunodeficiency Virus (HIV)
- •- Active hepatitis B or hepatitis C
- •- Severe infections at the time of enrollment
- •- Significant cardiovascular disease
- •- Prior treatment with immune checkpoint blockade therapies, anti-PD1 and anti-PD-L1 therapeutic antibody
研究者
相似试验
进行中（未招募）
不适用
A Phase III, randomized, double blind study of the safety and efficacy of GSK1349572 50 mg once daily to raltegravir 400 mg twice daily both administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral therapy na?ve adult subjects. - ING113086treatment- na?ve, HIV infected adultsMedDRA version: 9.1Level: LLTClassification code 10002725EUCTR2009-017950-11-ITViiV Healthcare UK Ltd788
进行中（未招募）
1 期
A Phase III, randomized, double blind study of the safety and efficacy of GSK1349572 50 mg once daily to raltegravir 400 mg twice daily both administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral therapy naïve adult subjects.EUCTR2009-017950-11-GBViiV Healthcare UK Ltd822
进行中（未招募）
1 期
A Phase III, randomized, double blind study of the safety and efficacy of GSK1349572 50 mg once daily to raltegravir 400 mg twice daily both administered with fixed-dose dual nucleoside reverse transcriptase inhibitor therapy over 96 weeks in HIV-1 infected antiretroviral therapy naïve adult subjects.HIV-1 infected antiretroviral (ART) - naïve adult subjectsMedDRA version: 12.1Level: LLTClassification code 10008922Term: Chronic infection with HIVEUCTR2009-017950-11-FRViiV Healthcare UK Ltd822
进行中（未招募）
1 期
Study to test a new drug dolutegravir vs. raltegravir for HIVpatients who have never taken HIV medication.HIV-1 infected antiretroviral (ART) - naïve adult subjectsMedDRA version: 14.0Level: LLTClassification code 10008922Term: Chronic infection with HIVSystem Organ Class: 10021881 - Infections and infestationsEUCTR2009-017950-11-DEViiV Healthcare UK Ltd788
进行中（未招募）
1 期
A study of atezolizumab compared to placebo for subjects with late relapse ovarian cancer receiving a treatment with platinum-basedchemotherapy and bevacizumab.EUCTR2015-005471-24-FRARCAGY-GINECO405